Melanie Ivarsson
Corporate Officer/Principal chez MODERNA, INC.
Profil
Melanie Ivarsson is currently the Director at Loqus23 Therapeutics Ltd.
and the Chief Development Officer at Moderna, Inc. Previously, she worked as the Vice President & Head-Global Clinical Operations at Takeda Pharmaceuticals U.S.A., Inc. Dr. Ivarsson holds a doctorate from the University of Bristol and an MBA from MIT Sloan School of Management.
Postes actifs de Melanie Ivarsson
Sociétés | Poste | Début |
---|---|---|
MODERNA, INC. | Corporate Officer/Principal | 30/01/2020 |
Loqus23 Therapeutics Ltd.
Loqus23 Therapeutics Ltd. BiotechnologyHealth Technology Loqus23 Therapeutics Ltd.engages in research and development of biotechnology. The company was founded on March 29, 2019 and is headquartered in in Reading, the United Kingdom. | Director/Board Member | 25/01/2022 |
Anciens postes connus de Melanie Ivarsson
Sociétés | Poste | Fin |
---|---|---|
Takeda Pharmaceuticals U.S.A., Inc.
Takeda Pharmaceuticals U.S.A., Inc. Pharmaceuticals: MajorHealth Technology Takeda Pharmaceuticals U.S.A., Inc. develops and markets pharmaceutical products. It offers metabolic and cardiovascular, respiratory and immunology, central nervous system, oncology, and general medicine products. The company was founded in 1998 and is headquartered in Deerfield, IL. | Corporate Officer/Principal | - |
Formation de Melanie Ivarsson
University of Bristol | Doctorate Degree |
MIT Sloan School of Management | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 1 |
---|---|
MODERNA, INC. | Health Technology |
Entreprise privées | 2 |
---|---|
Takeda Pharmaceuticals U.S.A., Inc.
Takeda Pharmaceuticals U.S.A., Inc. Pharmaceuticals: MajorHealth Technology Takeda Pharmaceuticals U.S.A., Inc. develops and markets pharmaceutical products. It offers metabolic and cardiovascular, respiratory and immunology, central nervous system, oncology, and general medicine products. The company was founded in 1998 and is headquartered in Deerfield, IL. | Health Technology |
Loqus23 Therapeutics Ltd.
Loqus23 Therapeutics Ltd. BiotechnologyHealth Technology Loqus23 Therapeutics Ltd.engages in research and development of biotechnology. The company was founded on March 29, 2019 and is headquartered in in Reading, the United Kingdom. | Health Technology |